Abstract

Approximately 71 million people worldwide are infected with the hepatitis C virus (HCV). Injectable drug use represents the most common route of transmission in Europe and other developed countries. We studied the molecular characteristics of the HCV infection among mono-infected people who used drugs (PWUD) in Italy. Among 208 PWUD with anti-HCV antibodies, 101 (48.6%) were HCV RNA-positive, the majority (47%) were infected with the HCV genotype (Gt)1a, followed by Gt3a (34.9%), Gt4 (9.1%), Gt1b (4.5%), and Gt2 (4.5%). Bayesian phylogenetic analyses of clustered HCV NS5B sequences from 66 HCV-positive PWUDs with available plasma samples indicated age and neighborhood proximity as the most common characteristics between closely related HCV strains. Population dynamics, as measured by a coalescent Bayesian skyline analysis, revealed an increase in HCV Gt1a infections from the mid-1980s to mid-1990s. While HCV Gt3a infections were first detected in the 1980s, patient numbers with this genotype subtype remained relatively constant. For both Gt1a and Gt3a, Birth–Death Bayesian Skyline analyses produced higher reproduction numbers post 2014. For earlier time intervals, slow growths were observed for both Gt1a and Gt3a with reproduction numbers (Re) of approximately 1. The evolutionary rates for Gt1a and Gt3a were estimated as 2.23 × 10−4 and 3.85 × 10−4, respectively.

Highlights

  • A total of 215 patients were identified as being anti-hepatitis C virus (HCV) antibody-positive; 7 were coinfected with HIV and excluded from the study

  • We demonstrated that despite national preventative measures against the spread of HCV infection, such as dissemination of information, needle exchange programs, and distribution of drug paraphernalia, HCV prevalence among

  • Four of our HCV RNA-positive study participants declared only using drug paraphernalia, reinforcing how sniffing equipment represents an important factor in HCV transmission [8,48]

Read more

Summary

Introduction

The WHO estimated that approximately 71 million people worldwide are infected with the hepatitis C virus (HCV), with 1.75 million new infections being reported every year [1]. Before the screening for anti-HCV antibodies was introduced in 1990, blood transfusion was the main risk factor for HCV infection [2]. In 1993, Western countries started using a nucleic acid amplification (NAT) test to detect the presence of HCV RNA. The availability of more sensitive tests led to a reduction in HCV prevalence. In Italy in 2013, the HCV RNA incidence rate in first-time blood donors was 2.5 per 100,000 [3].

Objectives
Methods
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call